WEINSTABL; Harald

Patent Applications and Registrations

Patent applications and USPTO patent grants for WEINSTABL; Harald.The latest application filed is for "new isoindolinone substituted indoles and derivatives as ras inhibitors".

Company Profile

6.8.11

WEINSTABL; Harald - Vienna AT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
New Isoindolinone Substituted Indoles And Derivatives As Ras Inhibitors App 20220144810 - MANTOULIDIS; Andreas ; et al.	2022-05-12
Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors Grant 11,304,929 - Weinstabl , et al. April 19, 2	2022-04-19
Tosylacetate Based Compounds And Derivatives Thereof As Phgdh Inhibitors App 20220008386 - WEINSTABL; Harald ; et al.	2022-01-13
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20210101912 - RAMHARTER; Juergen ; et al.	2021-04-08
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Grant 10,919,913 - Ramharter , et al. February 16, 2	2021-02-16
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Grant 10,882,866 - Gollner , et al. January 5, 2	2021-01-05
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Grant 10,717,742 - Gollner , et al.	2020-07-21
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Grant 10,576,064 - Weinstabl , et al.	2020-03-03
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20190169209 - RAMHARTER; Juergen ; et al.	2019-06-06
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Grant 10,246,467 - Ramharter , et al.	2019-04-02
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Grant 10,144,739 - Gollner , et al. De	2018-12-04
Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Grant 10,138,251 - Gollner , et al. Nov	2018-11-27
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20180291030 - GOLLNER; Andreas ; et al.	2018-10-11
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20180273541 - GOLLNER; Andreas ; et al.	2018-09-27
Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20170247394 - RAMHARTER; Juergen ; et al.	2017-08-31
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20170174695 - GOLLNER; Andreas ; et al.	2017-06-22
Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20160052938 - RAMHARTER; Juergen ; et al.	2016-02-25
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20160000764 - WEINSTABL; Harald ; et al.	2016-01-07
New Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one Compounds And Derivatives As Mdm2-p53 Inhibitors App 20150291611 - GOLLNER; Andreas ; et al.	2015-10-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.